Industry
Biotechnology
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA368 program for patients with human papillomavirus associated cancers. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
June 17, 2024 | 12:06 pm
Portfolio Pulse from Benzinga Insights
May 31, 2024 | 8:32 pm
Portfolio Pulse from Benzinga Newsdesk
May 29, 2024 | 8:02 pm
Portfolio Pulse from Benzinga Newsdesk
May 22, 2024 | 11:07 am
Portfolio Pulse from Benzinga Newsdesk
May 20, 2024 | 1:27 pm
Portfolio Pulse from Benzinga Newsdesk
May 09, 2024 | 8:46 pm
Portfolio Pulse from Benzinga Insights
May 07, 2024 | 8:31 pm
Portfolio Pulse from Benzinga Insights
April 08, 2024 | 8:31 pm
Portfolio Pulse from Benzinga Newsdesk
April 01, 2024 | 2:56 pm
Portfolio Pulse from Benzinga Newsdesk
March 28, 2024 | 3:12 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.